Opinion
Video
Author(s):
Jacqueline Barrientos, MD, MS, discusses the role of non-covalent BTK inhibitors in R/R CLL and provided concise comments on the latest data, including insights from the ongoing BRUIN and Bellwave trials.
Revisit Every OncLive On Air Episode From May 2024
Brown Highlights the Rationale for the RAMP-301 Trial in Low-Grade Serous Ovarian Cancer
CAR T-Cell Therapy Makes its Mark in CLL
Revisit the OncLive On Air Episodes From February 2024
Weighing the Benefits and Limitations of CAR T-Cell Therapy and Bispecific Antibodies in Multiple Myeloma
Pellini Discusses Immunotherapies and Current Limitations of ctDNA in Perioperative NSCLC
Linvoseltamab Generates Efficacy Similar to That Seen With Teclistamab in R/R Myeloma
Dostarlimab With Carboplatin/Paclitaxel Shows Survival Benefits in dMMR/MSI-H Endometrial Cancer
Pembrolizumab With Platinum-Based Therapy is Safe and Efficacious in PSCC
Dr Hughes on Efficacy Data for Asciminib in Newly Diagnosed Ph+ CP-CML